Trump Considers Starlink to Restore Internet Access in Iran Amid Protests 
Hanwha Ocean Shares Rise on Plans to Expand U.S. Shipbuilding Capacity 
Anthropic Launches HIPAA-Compliant Healthcare Tools for Claude AI Amid Growing Competition 
UBS Upgrades L’Oréal to Buy, Sees Strong Sales Momentum and 20% Upside 
Vitol to Ship First U.S. Naphtha Cargo to Venezuela Under New Oil Supply Deal 
Allegiant to Acquire Sun Country Airlines in $1.5 Billion Deal to Expand U.S. Leisure Travel Network 
FCC Approves Expansion of SpaceX Starlink Network With 7,500 New Satellites 
AustralianSuper Backs BlueScope Steel’s Rejection of $9 Billion Takeover Bid 
Stellantis to End Plug-In Hybrid Sales in the U.S. as Demand Shifts Toward Traditional Hybrids 
Rio Tinto–Glencore Merger Talks Spark Investor Debate Over Value, Strategy and Coal Exposure 
GM Takes $6 Billion EV Write-Down as Electric Vehicle Demand Slows in the U.S. 
xAI Cash Burn Highlights the High Cost of Competing in Generative AI 
Trump Pushes $100 Billion U.S. Oil Investment Plan for Venezuela After Maduro Seizure 
FTC Blocks Edwards Lifesciences’ JenaValve Acquisition in Major Antitrust Ruling 
Johnson & Johnson Secures Tariff Exemption by Agreeing to Lower Drug Prices in the U.S. 
Nvidia Appoints Former Google Executive Alison Wagonfeld as First Chief Marketing Officer 
NORCROSS, Ga., March 21, 2017 -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced today that the Company will release fourth quarter and full year 2016 results before the market opens on Tuesday, March 28, 2017. A copy of the earnings release will be available on the investor relations portion of the Company’s website at: http://galectintherapeutics.com/.
Management will provide a business update and conduct a question and answer session via a conference call beginning at 9:00 a.m. ET, Tuesday, March 28, 2017.
To access the conference call dial 844-899-6544 and provide the operator with Pin Number 89964111.
Galectin also invites all interested parties to listen to its conference call via webcast at http://edge.media-server.com/m/p/exukm2jh. The webcast will also be available on the investor relations portion of the Company’s website at http://galectintherapeutics.com/. The webcast will be archived on the Company’s website within two hours of the live call.
About Galectin Therapeutics
Galectin Therapeutics is dedicated to developing novel therapies to improve the lives of patients with chronic liver and skin diseases and cancer. Galectin's lead drug (GR-MD-02) is a carbohydrate-based drug that inhibits the galectin-3 protein which is directly involved in multiple inflammatory, fibrotic, and malignant diseases. The lead development program is in non-alcoholic steatohepatitis (NASH) with cirrhosis, the most advanced form of NASH related fibrosis. This is the most common liver disease and one of the largest drug development opportunities available today. Additional development programs are in treatment of severe atopic dermatitis, moderate-to-severe plaque psoriasis, and in combination immunotherapy for advanced melanoma and other malignancies. Galectin seeks to leverage extensive scientific and development expertise as well as established relationships with external sources to achieve cost-effective and efficient development. Additional information is available at www.galectintherapeutics.com.
Contact: Jack Callicutt, Chief Financial Officer (678) 620-3186 [email protected]
